TAIPEI, March 28, 2026 /PRNewswire/ — Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today provided an update on the plant-derived innovative drug MCS®-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).

• Pioneering Plant-Based Therapeutics
  Developed in Taiwan, MCS®-2 is the world’s only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia (BPH). Jyong Biotech has conducted four Phase III clinical trials (API-1) in the U.S. and Taiwan, including two pivotal trials (one in the U.S. and one in Taiwan) and two open-label extension studies (one in the U.S. and one in Taiwan), and completion of the Phase III clinical trial report was achieved in 2017.

  In the U.S., trials were conducted across 27 centers in 19 states, involving over 200 urologists. In Taiwan, trials took place in 12 major hospitals, including multiple medical centers, with participation from more than 70 urologists (over one-tenth of all urologists in Taiwan). The Company believes that this extensive physician network lays a strong foundation for future commercialization and expansion into new indications.

• Rigorous Scientific Validation and Clinical Evidence:
  Jyong Biotech strictly adheres to FDA guidelines and standards throughout its drug development process. MCS®-2 (API-1) has completed Phase I through Phase III clinical validation, along with more than ten international toxicology studies. Across all four Phase III trials in Taiwan and the U.S., the drug demonstrated excellent safety, with no serious adverse events, supporting its suitability for long-term use.
• Global Patent Protection:
  The company believes that its core technology significantly enhances bioavailability and enables the development of multiple formulations and indications, including oral formulations, injectable forms, and bladder instillation therapies. These innovations are protected by patents across the Americas, Asia, Europe, and other regions, forming a global portfolio that effectively overcomes existing patent barriers established by major pharmaceutical companies.
• Large Market Potential for Target Indications:
  BPH/LUTS is a common age-related condition affecting hundreds of millions of men worldwide.

  Current treatments for BPH/LUTS are associated with side effects and drug resistance, impacting patient compliance and satisfaction. There is therefore an urgent unmet need for a safe, long-term therapeutic solution. MCS®-2 is being developed to address this gap, offering clear competitive advantages.

  The Company believes that with global population aging and increasing healthcare demand, the market for prostate disease treatment and prevention presents substantial growth potential. Jyong Biotech remains committed to advancing innovative R&D to provide safer, evidence-based solutions.

  Since its establishment, Jyong Biotech has remained committed to innovation and R&D, continuously expanding its scope and vision. The company places strong emphasis on quality and regulatory compliance, strictly adhering to international standards to ensure the safety and quality of its products. Through these efforts, Jyong Biotech believes that it is well-positioned to enter global markets, promote cross-border collaborations and licensing models, and create broader opportunities for partnerships worldwide.

“We are proud to lead the development of Taiwan’s first oral botanical new drug to advance into Phase III clinical trials,” stated Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “MCS®-2 reflects our commitment to innovation and has the potential to provide safer, long-term solutions for patients with BPH/LUTS. We look forward to expanding our global impact through continued research and development.”

As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO^®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.

For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com

Investor Relations
WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214

WEST HAVEN, Conn., March 28, 2026 /PRNewswire/ — World-renowned forensic scientist Dr. Henry C. Lee passed away peacefully on Friday, March 27, at his home in Henderson, Nevada, displaying remarkable strength, grace and resilience during a brief illness. He was 87 years old. His passing was announced by his family, in conjunction with the University of New Haven, where he served as a distinguished professor for more than 50 years.

In his final days, Dr. Lee was finalizing a book regarding missing-persons investigations, which will be published in the near future. He has authored or co-authored more than 40 books. 

Dr. Lee joined the University of New Haven in 1975 and founded the University’s forensic science program, developing it from a small classroom equipped with a single fingerprint kit into an internationally recognized multi-disciplined academic department considered one of the nation’s best. 

In 1998, he founded the Henry C. Lee Institute of Forensic Science, and, in 2010, the University opened an ultra-modern home for the institute, a three-story, 15,000 square-foot facility featuring the most cutting-edge forensics investigation technology, including a crime scene center, a high-tech forensic room, a crisis management center, and a state-of-the-art learning center. ”The Institute will become a catalyst enabling professionals in the field to work together,” Dr. Lee said at its unveiling. “The world then becomes a small community engaged in fighting crime.” 

For more than 20 years while at the University of New Haven, Dr. Lee served as chief criminalist for the State of Connecticut and director of the Connecticut State Police Forensic Science Laboratory from 1978 to 2000 and was Commissioner of the state’s Department of Public Safety and Connecticut State Police from 1998-2000. He was Chief Emeritus for the state of Connecticut’s Division of Scientific Services from 2000 to 2010.

Throughout his legendary career, Dr. Lee has served as a forensics expert in all 50 states and more than 46 countries, and has lectured in more than 70 countries. He has been a consultant for 600 law enforcement agencies and has testified more than 1,000 times in both criminal and civil courts in the United States and abroad, most notably in the O.J. Simpson case. For some of the highest-profile cases, Dr. Lee provided investigative assistance, including the murder of JonBenét Ramsey, the Helle Crafts woodchipper murder, the Laci Peterson case, the death of Chandra Levy, the kidnapping of Elizabeth Smart, 9/11 forensics investigation, and the reinvestigation of the John F. Kennedy assassination. 

Dr. Lee was born November 22, 1938, in Rugao, Jiangsu, China, where a multi-story museum stands in his honor. His family relocated to Taiwan where he received a Bachelor of Arts degree in police administration from the Taiwan Police College in 1960. He became a police officer in the Taipei Police Department, rising to captain at the age of 22, the youngest in Taiwanese history. 

Dr. Lee moved with his late wife to the United States in 1964. Dr. Lee earned his Ph.D. (1975) and master’s (1974) degrees in biochemistry from New York University, and a bachelor’s degree in forensic science from John Jay College (1972). Dr. Lee has been conferred 30 honorary degrees, including from the University of New Haven in 1991 and 2010. Dr. Lee was an emeritus member of the University’s Board of Governors for nearly 30 years.

Dr. Lee was pre-deceased by his wife Margaret Lee in 2017. He is survived by his daughter Sherry Hersey and son Stanley Lee, their respective spouses, Ted and Romy, and their four grandchildren, David Hersey and Rachel Hersey Hotaj, and Joseph and Alexander Lee, as well as his wife Angel Xiaping Jiang and her sons Yan Liu and Tianchen Liu.

The eleventh of 13 children, Dr. Lee credited his sister Dr. Sylvia Lee-Huang for supporting him throughout his studies and his career. Dr. Lee recently said, “Without the support of Dr. Sylvia Lee-Huang, there would be no Dr. Henry Lee.” 

Committed to giving back, he had contributed his speaking honoraria and major gifts over the years. Ever humble, he did not want a memorial or celebration of life.

Donations may be made in his memory to the Friends of Dr. Henry C. Lee Fund, which supports critical enhancements to laboratory spaces, equipment, and teaching facilities, ensuring that the Henry C. Lee College of Criminal Justice and Forensic Sciences remains at the forefront of forensic science education for generations to come. Special gifts may be discussed by emailing botis@newhaven.edu or calling 203-932-7263.

Friends may post comments, memories and photos on a Kudoboard page dedicated to Dr. Lee.

Read more about Dr. Lee’s legacy.

The edge in automated execution has less to do with smarter models than with market structure.

HONG KONG, March 28, 2026 /PRNewswire/ — Derivatives exchange OneBullEx, launched in October 2025, has built its entire platform architecture around futures execution from day one. Its infrastructure vertically integrates automated execution systems and strategy development tools directly into the exchange core, so that the path from strategy construction to live futures execution runs on a single infrastructure layer with no third-party API dependencies. The timing aligns with a broader industry shift. On March 3, CFTC Chairman Michael Selig told the Milken Institute’s Future of Finance conference that his agency would create a framework for crypto perpetual futures within weeks, aiming to bring onshore a trading instrument that has until now existed almost entirely on offshore exchanges. The announcement followed a year of rapid movement: Coinbase launched CFTC-regulated perpetual-style futures for US retail traders in July 2025, Cboe introduced its own Continuous Futures for Bitcoin and Ethereum in December 2025, and Coinbase expanded into stock perpetual futures for non-US users in March 2026. Perpetual futures are becoming the default infrastructure layer for derivatives execution, and the US is racing to catch up.

AI technology is finding more and more applications across crypto. But in the execution layer specifically, its real home turns out to be futures. Futures contracts are standardized, margin-based, marked to market, and natively support both long and short exposure. These properties make systematic execution more straightforward than in spot markets, where execution logic gets tangled with custody, settlement, and borrowing mechanics. It is no surprise that automated execution has increasingly concentrated in derivatives, with perpetual futures accounting for more than 90% of global crypto derivatives trading volume.

This matters now because market participants are accelerating the shift from manual operations to automated execution. Processes that once depended on human screen-watching and manual order placement are increasingly being augmented by programmatic execution systems. Futures, with their built-in margin mechanics and contract-level standardization, are where execution automation becomes easiest to operationalize.

What Futures Give Machines That Spot Does Not

A spot trade means owning the asset outright. Even on a well-designed exchange with price-time priority matching, the execution system’s job mixes order logic with operational housekeeping: custody, settlement, and (if you want to express a bearish view) borrowing mechanics that vary by venue.

A futures contract strips that away. Positions are margin-based and marked to market continuously. Long and short exposure are symmetric by design, which means one execution framework can operate in both directions. Position sizing becomes a controllable parameter tied to margin rather than full notional ownership. Risk limits translate directly into margin thresholds. The granularity of risk and position management available to an execution system is finer, and the adjustable parameters are more explicit.

This is the logic behind platforms that choose to build around futures from the start. OneBullEx, a derivatives exchange launched in October 2025, made that choice explicitly. Its infrastructure is optimized for perpetual contracts and futures execution across 50+ trading pairs, with spot available as a secondary function. The platform architecture reflects the thesis that when execution systems need standardized inputs, symmetric positioning, and margin-based risk controls, futures-first design removes an entire layer of friction that spot-first platforms carry as legacy.

For an automated execution system, that difference changes how risk management, position calculation, and order handling work. Margin and mark-to-market are standard foundational mechanisms in futures markets, expressed through standardized terms, central clearing, margin as a performance bond, and daily settlement. These are the same features that make futures liquid and scalable, and they also make the market easier to turn into rules-based execution architectures.

In crypto perpetuals, the contract never expires. A funding rate (typically settled every eight hours) serves as the anchoring mechanism, pulling the perpetual price back toward spot. That rate is derived from the recent gap between futures and spot prices. On OneBullEx, this mechanism works as a regular fee exchanged between long and short holders, with the direction of payment determined by whether the contract trades above or below spot. For systematic execution, funding is an extra state variable. It reflects the real-time tilt in positioning and leverage distribution between longs and shorts. This signal does not exist in spot markets.

The Signals Automated Execution Finds Only in Derivatives

Futures markets produce data layers that spot order books lack. This is the most underappreciated reason automated execution gravitates toward derivatives.

Basis (the spread between spot and futures prices) and funding (the periodic cash exchange between longs and shorts in perpetuals) are anchoring signals native to derivatives markets. They tell an execution system how far derivatives have drifted from the underlying, and in which direction leverage is leaning. A system can treat that gap as a feature input, a risk control signal, or both.

Open interest adds a second layer of market intent. When perpetuals account for the majority of both volume and open interest in crypto futures, the positioning information embedded in derivatives becomes the densest available. Microstructure patterns, liquidation cascades, and sentiment proxies tend to surface there first, because that is where participants express conviction through leveraged capital. Where the signal is densest, the execution system should be running.

The question of signal transparency matters for how execution systems are evaluated. OneBullEx’s 300 SPARTANS marketplace, which hosts up to 300 automated execution systems each running distinct futures strategies, publishes every bot’s performance through Net Asset Value tracking with time-weighted rate of return calculations. Every order book, every trade history, and every position is visible and auditable. This kind of glass-box visibility gives execution systems and the users who subscribe to them the ability to verify performance against actual market conditions, rather than relying on backtested claims.

Order execution follows the same logic. In futures-style order books, where contract specs are standardized and matching rules are explicit, granular order-book data is a natural candidate for machine learning. Execution optimization and order-book modelling are technical use cases native to derivatives, growing organically from the market structure. On a spot-first infrastructure, they become patches awkwardly bolted on.

Why Price Discovery Matters for Automated Execution

A less obvious advantage: futures often lead the price discovery process.

Research on spot-futures price dynamics consistently finds that futures contribute a majority share of price discovery under typical conditions, with an even larger role when arbitrage signals are present. In crypto, standard price-discovery measures point to futures dominating. Deviations between futures and spot predict spot returns, while the reverse does not hold. Information moves from futures to spot, on average, with a lag.

Foreign exchange markets offer a useful reference. In periods when the spot market was less transparent, futures showed disproportionate information content and sometimes led spot by minutes. As spot transparency improved, the information share shifted. The lesson is clear: market design and transparency decide where informed capital concentrates. Futures venues, architected as centralized, rule-based auction environments with machine-legible transparency, naturally attract that capital. For systematic execution, the mapping from market state to order action is cleaner to learn where the signal is concentrated.

Higher Execution Efficiency Does Not Mean Lower Risk

Futures compress time. Leverage amplifies both profit and loss. Margin is a performance bond, and traders must post additional variation margin when accounts fall below maintenance levels. Crypto perpetuals are high-leverage instruments by design, and the details of order protection directly affect execution system outcomes. For example, when the spread between the latest contract price and a reasonable benchmark exceeds a threshold, a triggered take-profit or stop-loss order can be rejected. Any execution system operating on the venue must incorporate these rules into its modelling.

Automated execution systems need to get several things right at once: slippage assumptions must be conservative, operational monitoring must run continuously, and margin-mode awareness must be explicit across every position. A position can be liquidated even when funds exist elsewhere on the platform, depending on whether isolated or cross margin is active. OneBullEx addresses this directly in its platform design: its documentation walks users through how isolated margin confines risk to a single position while cross margin draws on the full account balance, and how choosing the wrong mode can lead to unexpected liquidation even when the overall account appears healthy. These are the details that determine whether an execution system survives a volatile session or gets caught by a margin call it failed to model.

The core requirement of automated execution is structure, and speed is only one dimension. Structure means knowing how a market behaves when things go wrong.

Where This Leads

The structural fit between automated execution technology and futures markets is driving a new class of futures-native platforms, designed around derivatives infrastructure from the start, with execution automation embedded in the trading architecture.

OneBullEx represents this design philosophy in practice. Beyond 300 SPARTANS, its OneALPHA product provides a natural-language-driven strategy development tool that routes a user’s described execution logic through five specialized processing stages, from hypothesis generation and code construction to walk-forward validation and infrastructure management, producing a deployable futures execution framework without requiring the user to write code. The platform’s design allows strategy creators to focus on execution logic and validation quality, with the infrastructure handling deployment, monitoring, and operational stability.

The broader pattern matters more than any single platform. Automated execution technology is most likely to mature first in futures, because futures were built for structured execution.

Execution technology will keep getting better. The market discipline it depends on is not new. Futures were built for it.

About OneBullEx

OneBullEx is a next-generation derivatives trading platform offering USDT-settled perpetual futures, automated trading systems, and secure infrastructure for global users. Powered by OneMore Group, OneBullEx combines institutional-grade oversight with cutting-edge trading technology to provide a stable, transparent, and efficient environment for traders worldwide.